ABEC to supply customized large-scale bioreactor trains to Qilu
cGMP manufacturing sites in China
BETHLEHEM, Pa.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/Onlyabec?src=hash" target="_blank"gt;#Onlyabeclt;/agt;–ABEC,
a global provider of integrated solutions and services for
biopharmaceutical manufacturing, today announced Qilu Pharmaceutical Co.
has again selected ABEC for their production capacity expansion for two
cGMP manufacturing sites in Jinan, Shandong, China. ABEC is delivering
multiple fully-customized cell culture bioreactor trains up to 6,000L to
support Qilu’s robust recombinant monoclonal antibody product pipeline.
ABEC has been providing bioreactor systems to Qilu for 10 years, and
this expansion builds on that success.
The bioreactor trains will be installed in facilities at Qilu’s
Biopharmaceutical Industrial park, which is one of the largest
biopharmaceutical industrial parks in China. As a leading enterprise of
the China pharmaceutical industry, Qilu has been accelerating
development of its biopharmaceutical business footprint in recent years.
Qilu Biopharmaceutical Industrial Park is of great significance to
Jinan’s 100 billion biopharmaceutical industry program. Qilu has been
exporting its products to over 70 countries worldwide.
“As a leading multinational pharmaceutical company in China, Qilu has
been focusing on developing innovative drugs and building world class
cGMP production facilities,” said Yan Li, CEO, Qilu Pharmaceutical,
Co. “With our dedication to making a healthier world, and close
collaboration with our partners globally, Qilu aspires to be among the
top pharmaceutical companies in the world.”
“ABEC’s first project in China was with Qilu Pharmaceutical in 2009,”
said Scott Pickering, ABEC President and CEO. “We value this
long-term partnership and are honored to support Qilu’s ongoing efforts
to bring lifesaving product to patients worldwide.”
Since 1974, ABEC has been a leader in delivering integrated process
solutions and services for manufacturing in the biopharmaceutical
industry. A majority of the world’s pharmaceutical and biotech companies
are ABEC customers with many of today’s leading therapies manufactured
by processes and equipment engineered, manufactured, installed and
serviced by ABEC. ABEC’s unique value is based on long experience,
complete in-house capabilities, a custom, flexible approach, and
long-term credibility. Whether adding capacity or improving existing
facilities ABEC’s turn-key solutions and support services reduce overall
cost and time to market while delivering maximum productivity. Visit: abec.com,
email [email protected].
Susan Cooper Curcio
Director of Marketing
(610) 861 4666